AMX208 is a potent oral small molecule inhibitor classified as a pyrazolopyridine derivative, developed to target the c-MET receptor for the potential treatment of non-small cell lung cancer and various… Read more
AMX208 is a potent oral small molecule inhibitor classified as a pyrazolopyridine derivative, developed to target the c-MET receptor for the potential treatment of non-small cell lung cancer and various solid tumors characterized by c-MET overexpression. This category provides essential tools for pharmaceutical and analytical researchers, including the parent drug, alongside stable isotope labelled compounds such as AMX208-d3 and AMX208-13C-d3. These reference standards are critical for high-precision analytical testing, particularly in the development of robust LC-MS/MS methods. By serving as internal standards, these labelled analogues enable accurate quantification and precise impurity profiling of the drug substance within complex biological matrices. Laboratories rely on these high-quality materials for method validation, structural elucidation, and rigorous quality control protocols during both preclinical and clinical research phases to ensure the integrity of experimental data regarding this c-MET inhibitor.